Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the Relationship Between the Blood Levels of Soluble PDL1 and β2-microglobulin, and the Clinical Course of a Metastatic Solid Tumor Treated With a First-line Therapeutic of Checkpoint Immune Inhibitor

NCT05426317 is registered in ClinicalTrials.gov with University Hospital, Clermont-Ferrand as lead sponsor.

NCT NCT05426317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05426317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the Relationship Between the Blood Levels of Soluble PDL1 and β2-microglobulin, and the Clinical Course of a Metastatic Solid Tumor Treated With a First-line Therapeutic of Checkpoint Immune Inhibitor
Lead sponsor
University Hospital, Clermont-Ferrand
Phase
Not applicable
Overall status
Unknown status
Start date
February 10, 2022
Completion date
February 29, 2024
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, non small cell lung cancer, renal cancer